MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ
6.72
+0.20
+3.07%
After Hours: 6.41 -0.31 -4.61% 19:54 03/28 EDT
OPEN
6.54
PREV CLOSE
6.52
HIGH
6.77
LOW
6.41
VOLUME
2.24M
TURNOVER
0
52 WEEK HIGH
13.50
52 WEEK LOW
3.670
MARKET CAP
698.30M
P/E (TTM)
-2.7820
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at COGT last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at COGT last week (0311-0315)?
Weekly Report · 03/18 09:16
Weekly Report: what happened at COGT last week (0304-0308)?
Weekly Report · 03/11 09:16
Weekly Report: what happened at COGT last week (0226-0301)?
Weekly Report · 03/04 09:16
U.S. RESEARCH ROUNDUP-Agiliti, Domino's Pizza, Krystal Biotech
Wall Street analysts revise their ratings and price targets on several U.S. Listed companies. Agiliti, Domino's Pizza, Krystal Biotech, and Eli Lilly among companies with revised targets. Agilti cut to hold from buy, while others raise their targets.
Reuters · 02/27 07:31
Weekly Report: what happened at COGT last week (0219-0223)?
Weekly Report · 02/26 09:18
Weekly Report: what happened at COGT last week (0212-0216)?
Weekly Report · 02/19 09:18
Cogent Biosciences Inc: Statement of acquisition of beneficial ownership by individuals
Press release · 02/14 21:44
More
About COGT
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Webull offers Cogent Biosciences Inc stock information, including NASDAQ: COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.